###### Strengths and limitations of this study

-   Addresses the question of whether patients with non-valvular atrial fibrillation (NVAF) who are well controlled on warfarin could continue to be reliably anticoagulated with warfarin.

-   Population-based study of all adults with NVAF in an entire Canadian province, with complete capture of all interactions with the healthcare system, prescribing data and international normalised ratio (INR) results.

-   We assumed the target INR ranges were 2--3 for all patients, but recognised that for a small proportion of patients with NVAF, a higher (or lower) range may be targeted clinically.

-   We focused solely on INR control and did not examine clinical endpoints.

Although warfarin has been shown to be efficacious in preventing stroke in non-valvular atrial fibrillation (NVAF), its effectiveness is dependent on being in therapeutic range (international normalised ratio (INR) between 2 and 3).[@R1] However, some practice-based studies suggest that only a minority of patients anticoagulated in the community have an average INR between 2 and 3, with wide variability from 29% to 75%.[@R1] The time in therapeutic range (TTR) is a standard measure of warfarin control which incorporates both the frequency of INR measurement and the actual values to interpolate daily INR values and define the percentage of time in range for each patient.[@R7] A TTR of at least two-thirds is often used as the cutpoint for defining 'good INR control' as patients randomised to warfarin in the clinical trials proving the efficacy of anticoagulation had their INRs within target range 65% of the time,[@R2] a large cohort with 63% of INRs in the 2--3 range reported warfarin benefits similar to those in the randomised trials[@R3] and a post-hoc analysis of the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE-W) Trial demonstrated that warfarin-treated patients with [\<]{.ul}65% of their INRs between 2 and 3 had higher rates of embolic and bleeding events than antiplatelet-treated patients.[@R4]

One of the key arguments in favour of the direct oral anticoagulants for NVAF is that the TTR for warfarin-treated patients is unpredictable and may well be markedly lower in clinical practice than in the randomised trials proving the efficacy of warfarin. While this is certainly a rationale for choosing a direct oral anticoagulant as the first agent for a patient newly diagnosed with NVAF, as clinicians we are often faced with the issue of what to do with patients who have been well controlled on warfarin---can such patients be left on warfarin or should we be switching them to direct oral anticoagulants?

A recent report from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) raised concern that even when patients initially exhibit good INR control, this may fluctuate substantially over time: they reported that only 34% of their patients with outstanding INR control (TTR ≥80%) in the first 6 months of observation continued to exhibit that degree of control over the subsequent year.[@R8] However, as care varies widely across regions[@R1] and almost 80% of ORBIT-AF patients were enrolled from specialist offices, we designed this study to examine the adequacy of anticoagulation in an entire population more closely reflecting usual clinical practice where most patients with NVAF are managed by primary care physicians. We examined the TTR and stability of INR control over time in a population-based cohort of adults with NVAF in a universal access healthcare system similar to the British National Health Service (the entire Canadian province of Alberta). As a secondary goal, we evaluated whether TTR and INR stability varied by kidney function.

Methods {#s1}
=======

Design {#s1a}
------

Retrospective cohort study using routinely collected health data.

Data sources {#s1b}
------------

As described in full elsewhere,[@R11] we used de-identified but linked (using unique health number identifiers) Alberta Health administrative and laboratory databases including all residents of Alberta (population 4.3 million people). This project was approved by Alberta Health and the Health Research Ethics Boards at the University of Alberta and the University of Calgary with a waiver of individual signed patient consent (since data was de-identified).

Study sample {#s1c}
------------

The cohort consisted of all adult Albertans (aged ≥18 years) with a diagnosis of AF (International Classification of Diseases - 9 (ICD-9) Canadian Modification (CM) 427.3 or ICD-10 I48) between 1 January 2008 and 31 March 2015 in any fields of either the discharge abstract database (which captures most responsible diagnosis and up to 24 secondary diagnoses for all acute care hospitalisations), the national ambulatory care reporting system (which captures all visits to emergency rooms or hospital-based specialist clinics in Alberta), or the physician billing claims databases (see online [supplementary file 1](#SP1){ref-type="supplementary-material"} for case definitions for NVAF and all covariates listed below). Patients with a history of mitral or aortic valvular disease, valve surgery (see online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}) or end-stage kidney disease (defined as documented chronic dialysis or prior kidney transplant before the onset of NVAF) were excluded ([figure 1](#F1){ref-type="fig"}). These NVAF case definitions have been evaluated in multiple studies, with sensitivity approaching 95% and specificity 99% in those who use both inpatient and outpatient data (as we did).[@R12] We restricted this study to patients with dispensed warfarin prescriptions of ≥30 days (we linked to the Pharmacy Information Network and Alberta Blue Cross to obtain all prescription dispensations for cohort patients of any age). In the secondary analysis by kidney function, we restricted our analysis to only those with an outpatient serum creatinine measured at least once in the 18 months after the index date.
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![Participant flow: AKDN (dataset containing administrative records for all 4.6 million Albertans) and NVAF. Note that percentages in the last row of boxes reflect the proportions among patients still prescribed warfarin in that time frame. AKDN, Alberta Kidney Disease Network; ESRD, end-stage renal disease; INR, international normalised ratio; NVAF, non-valvular atrial fibrillation; TTR, time in therapeutic range.](bmjopen-2017-016980f01){#F1}

Covariates {#s1d}
----------

As described fully elsewhere,[@R11] we identified comorbidities using the ICD-9-CM or ICD-10-CA codes validated in administrative databases (with look-back beginning in April 1994) and we used estimated glomerular filtration rate (eGFR) (calculated using the Chronic Kidney Disease - Epidemiology (CKD-EPI) equation) to categorise patients by kidney function at baseline.

Definition of INR control {#s1e}
-------------------------

To examine adequacy of anticoagulation, we examined the frequency of INR monitoring and results over subsequent time frames. We excluded INRs done during the initialisation phase for warfarin (defined as within 30 days of the first warfarin prescription) and, after setting time zero as day 31, we used the outpatient INR values in months 1--6 after the initial prescription to classify patients as having 'good control' (TTR [\>]{.ul}65%) or suboptimal control (TTR \<65%). We calculated TTR using the method of Rosendaal, which incorporates both the frequency of INR measurement and the actual values to interpolate daily INR values and define the percentage of time in range for each patient.[@R7] We also examined the frequency of extreme INR values (\<1.5 or \>4.0 as previously defined in the literature[@R8])---in order to not falsely attribute periods during which warfarin was deliberately held for surgical or diagnostic procedures or acute illnesses, we excluded all values drawn within 1 week before or after a hospitalisation (in Alberta all biopsy procedures or surgeries are done in publically funded hospital settings and thus captured in the discharge abstract database or the national ambulatory care reporting system).

Follow-up {#s1f}
---------

We followed all study participants for 18 months from the time they met the warfarin-treated NVAF case definition (ie, had been on warfarin for at least 30 days) or until they stopped warfarin, they left the province, died, or 31 March 2015, whichever came first.

Statistical analysis {#s1g}
--------------------

All analyses were completed in Stata/MP V.13.1 ([www.stata.com](www.stata.com)). Descriptive statistics were reported as counts and percentages, or medians and IQR, as appropriate. TTR is reported at 1--6, 7--12 and 13--18 months. In order to examine the association between TTR at 1--6 months with TTR at 7--12 months and 13--18 months, we used logistic regression. Outcomes were regressed on age (categorised as 65--74, 75--84 and ≥85 years), sex, rural or urban residence, eGFR (≥60, 45--59, 30--44 and \<30 mL/min×1.73 m^2^) and comorbidities (prior myocardial infarction, prior stroke or transient ischaemic attack, alcohol misuse, metastatic cancers, non-metastatic cancers, chronic heart failure, chronic pulmonary disease, cirrhosis, dementia, diabetes mellitus, epilepsy, hypertension, peptic ulcer disease and peripheral vascular disease). McFadden's pseudo R^2^ (<http://stats.idre.ucla.edu/other/mult-pkg/faq/general/faq-what-are-pseudo-r-squareds/>) and the likelihood ratio test were used to compare models with and without adjustment for good control in the first 6 months. p\<0.05 was considered statistically significant.

Results {#s2}
=======

Of 57 669 patients with NVAF dispensed warfarin ([figure 1](#F1){ref-type="fig"}), 17 099 (29.7%) did not have at least three INRs measured in months 1--6. Of the 40 570 who did have at least three INRs measured in months 1--6 (median number of INRs 11, IQR 7--16), 16 639 (41.0%) demonstrated good control (TTR [\>]{.ul}65%) and 23 931 (59.0%) had suboptimal control (at least three INRs drawn but TTR \<65%) ([figure 1](#F1){ref-type="fig"}). Longer term, of the 16 639 patients who demonstrated good control in the first 6 months, 8177 (57.1% of those who remained on warfarin) exhibited TTR [\>]{.ul}65% in months 7--12 and 6804 (56.8% of continuing warfarin users) had TTR [\>]{.ul}65% in months 13--18 ([figure 1](#F1){ref-type="fig"}). Of the 17 099 patients having less than three INRs measured in months 1--6 after starting warfarin, 11 653 had refills for warfarin extending beyond 7 months---as warfarin may be ingested differently than prescribed, we cannot tell exactly when (or if) the other 5446 patients with infrequent INR monitoring actually stopped taking warfarin.

Patients were more likely to have good INR control in months 1--6 if they lived in a rural area, were older or had a lower CHADS score (with lower frequencies of heart failure, stroke and diabetes but not hypertension) ([tables 1 and 2](#T1 T2){ref-type="table"}). In fact, all comorbidities (except hypertension), including worsening degrees of kidney dysfunction, were associated with less likelihood of good INR control ([table 2](#T2){ref-type="table"}, [figure 2](#F2){ref-type="fig"}). Despite being less likely to have TTR [\>]{.ul}65%, patients with CHADS scores of ≥2 had a higher frequency of INR measurements (median 11 (IQR 7--17)) during months 1--6 and median 8 (IQR 6--13) in months 7--18) than patients with CHADS scores of 1 or 0 (median 9 (IQR 6--14)) during months 1--6 and median 7 (IQR 4--11) in months 7--18).

![Proportion of patients with at least three INRs in months 1--6 and TTR \>65% in different time frames, broken down by eGFR, INR, GFR, TTR. The height of the bars shows the percentage of participants who meet the target in each 6-month interval of follow-up. The green bars represent all participants (followed and on anticoagulants) including those without eGFR in the first 6 months. The remaining four colours represent participants with varying levels of eGFR (mL/min×1.73 m^2^) in the first 6 months. eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate; INR, international normalised ratio; TTR, time in therapeutic range.](bmjopen-2017-016980f02){#F2}

###### 

Baseline characteristics by time in therapeutic range in months 1--6 of warfarin use

  ------------------------------------------------------------------------------------------------------------------------------------------------
                                Overall\        Time in therapeutic range \<65% or infrequent INRs\   Time in therapeutic range \>65%\   p Value
                                (n=57 669)      (n=41 030)                                            (n=16 639)                         
  ----------------------------- --------------- ----------------------------------------------------- ---------------------------------- ---------
  Age (years)                                                                                                                            \<0.001

   65--74                       13 112 (22.7)   9538 (23.2)                                           3574 (21.5)                        

   75--84                       15 265 (26.5)   10 663 (26)                                           4602 (27.7)                        

   ≥85                          29 292 (50.8)   20 829 (50.8)                                         8463 (50.9)                        

  Female                        25 655 (44.5)   18 334 (44.7)                                         7321 (44.0)                        0.13

  Rural residence               7670 (13.3)     5325 (13.0)                                           2345 (14.1)                        \<0.001

  CHADS~2~ score                2 (2,4)         3 (2,4)                                               2 (1,3)                            \<0.001

  Prior myocardial infarction   8304 (14.4)     6108 (14.9)                                           2196 (13.2)                        \<0.001

  Prior stroke/TIA              15 786 (27.4)   11 350 (27.7)                                         4436 (26.7)                        0.01

  Alcohol use disorder          2736 (4.7)      2268 (5.5)                                            468 (2.8)                          \<0.001

  Cancer, metastatic            1639 (2.8)      1327 (3.2)                                            312 (1.9)                          \<0.001

  Cancer, non-metastatic\*      5201 (9.0)      3865 (9.4)                                            1336 (8.0)                         \<0.001

  Chronic heart failure         24 216 (42.0)   18 096 (44.1)                                         6120 (36.8)                        \<0.001

  Chronic pulmonary disease     18 615 (32.3)   13 841 (33.7)                                         4774 (28.7)                        \<0.001

  Cirrhosis                     286 (0.5)       232 (0.6)                                             54 (0.3)                           \<0.001

  Dementia                      5418 (9.4)      4228 (10.3)                                           1190 (7.2)                         \<0.001

  Diabetes mellitus             16 951 (29.4)   12 396 (30.2)                                         4555 (27.4)                        \<0.001

  eGFR (mL/min×1.73 m^2)^                                                                                                                \<0.001

   ≥60                          19 031 (55.9)   13 390 (32.6)                                         5641 (33.9)                        

   45--59                       7830 (23.0)     5548 (13.5)                                           2282 (13.7)                        

   30--44                       5035 (14.8)     3740 (9.1)                                            1295 (7.8)                         

   \<30                         2135 (6.3)      1661 (4.0)                                            474 (2.8)                          

  Epilepsy                      1455 (2.5)      1137 (2.8)                                            318 (1.9)                          \<0.001

  Hypertension                  47 534 (82.4)   33 862 (82.5)                                         13 672 (82.2)                      0.30

  Peptic ulcer disease          549 (1.0)       445 (1.1)                                             104 (0.6)                          \<0.001

  Peripheral vascular disease   3482 (6.0)      2666 (6.5)                                            816 (4.9)                          \<0.001
  ------------------------------------------------------------------------------------------------------------------------------------------------

N (%) or median (IQR) as appropriate.

\*Specifically breast, cervical, colorectal, lung and prostate.

CHADS~2~, congestive heart failure, hypertension, age, diabetes, stroke/transient ischaemic attack; eGFR, estimated glomerular filtration rate; TIA, transient ischaemic attack.

###### 

Adjusted OR associated with TTR

  ---------------------------------------------------------------------------------------------------------------------------------------
                                                            1--6 months\              7--12 months\             13--18 months\
                                                            (n=34 023) aOR (95% CI)   (n=42 011) aOR (95% CI)   (n=42 959) aOR (95% CI)
  --------------------------------------------------------- ------------------------- ------------------------- -------------------------
  TTR ≥65%[\*](#tblfn4){ref-type="fn"} during months 1--6   --                        3.99 (3.81 to 4.17)       3.19 (3.05 to 3.34)

  Age (years)                                                                                                   

    65--74                                                  1.00                      1.00                      1.00

    75--84                                                  1.10 (1.02 to 1.18)       1.36 (1.27 to 1.47)       1.41 (1.31 to 1.52)

   ≥85                                                      1.10 (1.03 to 1.18)       1.49 (1.38 to 1.59)       1.57 (1.46 to 1.68)

  Female                                                    0.91 (0.86 to 0.95)       0.95 (0.91 to 1.00)       0.94 (0.90 to 0.99)

  Rural residence                                           1.13 (1.05 to 1.21)       1.09 (1.02 to 1.16)       1.15 (1.08 to 1.23)

  Prior myocardial infarction                               0.95 (0.88 to 1.01)       0.93 (0.87 to 0.99)       0.88 (0.82 to 0.94)

  Prior stroke/TIA                                          1.03 (0.97 to 1.08)       1.03 (0.98 to 1.08)       1.02 (0.98 to 1.08)

  Alcohol misuse                                            0.59 (0.51 to 0.67)       0.67 (0.59 to 0.76)       0.69 (0.61 to 0.78)

  Cancer, metastatic                                        0.61 (0.53 to 0.72)       0.59 (0.50 to 0.69)       0.60 (0.51 to 0.71)

  Cancer, non-metastatic†                                   0.89 (0.81 to 0.97)       0.90 (0.82 to 0.97)       0.88 (0.81 to 0.95)

  Chronic heart failure                                     0.81 (0.77 to 0.85)       0.95 (0.90 to 0.99)       0.96 (0.92 to 1.01)

  Chronic pulmonary disease                                 0.85 (0.81 to 0.90)       0.91 (0.86 to 0.95)       0.96 (0.91 to 1.01)

  Cirrhosis                                                 0.86 (0.62 to 1.21)       0.86 (0.61 to 1.21)       0.60 (0.41 to 0.87)

  Dementia                                                  0.72 (0.65 to 0.78)       0.83 (0.77 to 0.90)       0.75 (0.69 to 0.81)

  Diabetes mellitus                                         0.93 (0.89 to 0.98)       0.95 (0.91 to 1.00)       0.94 (0.90 to 0.99)

  eGFR (mL/min×1.73 m^2^)†                                                                                      

   ≥60                                                      1.00                      1.00                      1.00

    45--59                                                  1.00 (0.94 to 1.06)       1.01 (0.95 to 1.06)       0.99 (0.94 to 1.05)

    30--44                                                  0.89 (0.82 to 0.95)       0.97 (0.90 to 1.04)       0.92 (0.86 to 0.99)

   \<30                                                     0.77 (0.69 to 0.86)       0.78 (0.70 to 0.88)       0.85 (0.76 to 0.95)

  Epilepsy                                                  0.68 (0.57v0.80)          0.95 (0.82 to 1.10)       0.88 (0.76 to 1.01)

  Hypertension                                              1.06 (0.99 to 1.14)       1.15 (1.07 to 1.23)       1.15 (1.07 to 1.23)

  Peptic ulcer disease                                      0.69 (0.53 to 0.90)       0.64 (0.49 to 0.84)       0.82 (0.64 to 1.04)

  Peripheral vascular disease                               0.82 (0.74 to 0.91)       0.88 (0.80 to 0.96)       0.86 (0.79 to 0.95)
  ---------------------------------------------------------------------------------------------------------------------------------------

\*With at least 3 INRs in months 1--6.

†specifically breast, cervical, colorectal, lung and prostate.

aOR, adjusted OR; eGFR, estimated glomerular filtration rate; TIA, transient ischaemic attack; TTR, time in therapeutic range.

Of the 16 639 patients exhibiting good INR control in the first 6 months, 8177 (57.1% of those who remained on warfarin) exhibited TTR [\>]{.ul}65% in months 7--12 (median number of INR measurements 7, IQR 5,11) and 6804 (56.8% of continuing warfarin users) had TTR [\>]{.ul}65% in months 13--18 ([table 3](#T3){ref-type="table"}). Details on the frequency of INR measurements, the proportion of out-of-range INRs and the median TTRs in each time frame are provided in [table 4](#T4){ref-type="table"}. We further stratify INR control by TTR 65%--80% vs \>80% in [figure 3](#F3){ref-type="fig"};this demonstrates that the proportion of patients with excellent control (TTR \>80%) actually increased over time (p\<0.001 for trend). Good control in the first 6 months explained a significant amount of the variation in subsequent achievement of good control (pseudo R^2^ 0.084, likelihood ratio test p\<0.001 for months 7--12 and pseudo R^2^ 0.064, likelihood ratio test p\<0.001 for months 13--18) and exhibited reasonable discrimination for good control over the subsequent year (c index 0.685 (95% CI 0.679 to 0.691) for months 7--12 and c index 0.665 (95% CI 0.659 to 0.671) for months 13--18). Of the 14 330 patients exhibiting good INR control in 1--6 months and who continued on warfarin past 6 months, 6355 (44.3%) had at least one extreme INR value (\<1.5 or\>4.0) in the subsequent year. After exclusion of values drawn within 1 week of a hospitalisation, this proportion was 41.1%.

![Proportion of patients with TTR in various strata over time. The height of the bars shows the percentage of all participants (followed and on anticoagulants) that fall into each 'TTR' interval by each 6-month interval of follow-up. The black bars show the percentage of patients that met target \<65% of the time, the medium grey bars show the percentage of patients that met target between 65% and 80% of the time and the light grey bars show the percentage of patients that met target at least 80% of the time. TTR, time in therapeutic range.](bmjopen-2017-016980f03){#F3}

###### 

INR control (n=57 669)

  -------------------------------------------------------------------------------------------------------
                       \<3 INRs in months 1--6\   TTR \<65% in months 1--6\   TTR \>65% in months 1--6\
                       (n=17 099)                 (n=23 931)                  (n=16 639)
  -------------------- -------------------------- --------------------------- ---------------------------
  7--12 months                                                                

   Still on warfarin   11 653 (68.2)              18 641 (77.9)               14 330 (86.1)

   TTR \>65%           1157 (9.9)                 6699 (35.9)                 8177 (57.1)

  13--18 months                                                               

   Still on warfarin   9893 (57.9)                14 558 (60.8)               11 987 (72.0)

   TTR \>65%           1413 (14.3)                5879 (40.4)                 6804 (56.8)
  -------------------------------------------------------------------------------------------------------

INR, international normalised ratio; TTR, time in therapeutic range.

###### 

INR control in those with at least three INRs and TTR ≥65% in months 1--6 (n=16 639)

                          Months 1--6         Months 7--12       Months 13--18
  ----------------------- ------------------- ------------------ ------------------
  INR counts              9 (3,80)            7 (0,70)           7 (0,84)
  \>3.0, %                0.0 (0.0,35.0)      5.9 (0.0,100.0)    0.0 (0.0,100.0)
  \<2.0, %                12.5 (0.0,35.0)     13.0 (0.0,100.0)   12.5 (0.0,100.0)
  INR SD                  0.41 (0.00,3.26)    0.46 (0.00,5.70)   0.45 (0.00,5.66)
  Median TTR, % (range)   77.8 (65.0,100.0)   66.7 (0,100.0)     62.5 (0.0,100.0)

INR, international normalised ratio; TTR, time in therapeutic range.

Of the 41 030 patients who either had insufficient INR monitoring or exhibited suboptimal INR control during the first 6 months, 7856 (25.9% of those who remained on warfarin) met the definition of good INR control for months 7--12 and 7292 (29.8% of those who remained on warfarin during that time frame) for months 13--18 ([table 3](#T3){ref-type="table"}).

Discussion {#s3}
==========

We found that 30% of patients with NVAF dispensed warfarin had less than three INRs measured in months 1--6 (with approximately one-third of these patients having apparently stopped warfarin at some point in that first 6 months), and 41% of those who had regular INR measurements exhibited TTR of 65% or better. Just over half of those patients with good control in their first 6 months of warfarin therapy continued to exhibit good control over the subsequent 6 and 12 months. It is concerning that patients with higher CHADS scores or comorbidities were less likely to have INRs measured in the first 6 months and less likely to be in target range, suggesting a risk-treatment paradox in atrial fibrillation management in that higher risk patients appear to receive less optimal care.[@R15] A similar pattern was seen in the ORBIT-AF.[@R16] This may not necessarily reflect physician intent and may result from the fact that comorbidities such as heart failure, cirrhosis, cancer, alcohol misuse, kidney dysfunction and dementia can negatively impact TTR either through poorer medication adherence or biological variation in clotting factors (as are other factors such as malnutrition, fluctuating liver function and so on which are not captured by administrative databases).

Although there is a published prediction score for identifying patients who are more likely to have poor INR control,[@R17] this includes factors (such as ethnicity or tobacco use) which cannot be derived from administrative data and thus it has limited utility for comparative effectiveness research. Practitioner and healthcare system factors are also predictors of suboptimal TTR ratios in the literature.[@R9]

Our TTR and INR stability results are similar to those reported from ORBIT-AF in the USA,[@R8] but much lower than the levels of control reported in the Veterans Health Administration[@R10] and a recent Swedish nationwide study.[@R18] Although we suspect that the higher degree of INR control and better maintenance of that control over time in the Swedish and Veterans Administration (VA) studies reflects better integration and continuity of primary care in those settings, this cannot be definitively answered in observational studies such as these. However, results from a recent audit of 474 primary care physicians in Canada would support this contention as the median TTR for warfarin-treated patients with atrial fibrillation who had regular primary care physician follow-up was 75%.[@R19]

As we were able to link inpatient and outpatient administrative data, prescribing data and outpatient laboratory data to examine INR control for patients with NVAF in an entire Canadian province whether they were treated by primary care physicians or specialists, our results are generalisable to the broader population of patients with NVAF treated in a single-payer universal access healthcare system such as Alberta. Indeed, our study design avoids the potential selection biases that most AF registries are prone to. However, there are some limitations to our analysis. First, as we focused on patients newly initiated on warfarin, some may argue that this would artificially inflate their INR variability; however, we excluded inpatient and outpatient INRs drawn within the first 30 days of warfarin dispensation to limit this impact. Second, it could be argued that excluding patients who were prescribed warfarin for \<30 days may have introduced a selection bias but our interest was on patients chronically using warfarin. We have no information on why some patients stopped warfarin after \<30 days of therapy (in later years some may have in fact been switched to a novel direct oral anticoagulant which in the years studied was not covered publically in Alberta except with special authorisation). Third, we relied on pharmacy dispensation records to determine which patients were taking warfarin and acknowledge that warfarin may be ingested differently than prescribed or patients may be non-adherent even if filling prescriptions. Fourth, we assumed that the target INR ranges were 2--3 for all patients, but recognised that for a small proportion of patients with NVAF a higher (or lower) range may be targeted clinically if patients have had thromboembolic (or bleeding) events when INR was between 2 and 3. Fifth, we focused solely on INR control and did not examine clinical endpoints and any association with out-of-range values, although other studies have demonstrated a clear relationship between out-of-range INRs and bleeding or thromboembolic events.[@R4] It is important to acknowledge that some patients may still have events even if well anticoagulated, which may merely reflect the expected rate of non-cardioembolic strokes in patients of the same age, sex and comorbidity profile without NVAF rather than failure of anticoagulant treatment.[@R20]

While many of the early quality improvement studies in NVAF focused on warfarin dosing algorithms,[@R21] more recent studies[@R23] have highlighted the contribution of gaps in laboratory monitoring to suboptimal warfarin management---indeed we also found that a large subset of patients did not have sufficient INR values measured to calculate TTR. Our findings support the emphasis in current quality improvement efforts[@R24] to not only increase the use of dosing algorithms but to also encourage regular monitoring of INRs. Our findings also support those who argue for choosing a direct oral anticoagulant as the first agent for patients with NVAF given that future adherence with monitoring cannot accurately be predicted. However, our findings challenge the assumption that patients who have been well controlled on warfarin in clinical practice will invariably exhibit deteriorating control over time---one of the key arguments advanced in favour of switching from warfarin to the direct oral anticoagulants in chronically treated patients. We would agree with the authors of a recent nationwide audit from Sweden that 'well-managed warfarin therapy...is still a valid alternative for prophylaxis of AF-associated stroke'.[@R18]
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